OTLK
Outlook Therapeutics, Inc.2.4700
+0.3000+13.8%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
109.72MP/E (TTM)
-Basic EPS (TTM)
-0.84Dividend Yield
0%Recent Filings
8-K
New note refinances Avondale debt
Outlook Therapeutics issued an unsecured $18.4M promissory note to Atlas Sciences on March 16, 2026, at a $17M purchase price after $1.4M OID, solely to repay $17M of its $33.1M Avondale convertible note—leaving $10.8M outstanding. Avondale's maturity extended to December 31, 2026. New note carries 9.5%+ interest, matures in 15 months, with quarterly $3M redemptions allowed post-six months and 7.5% exit fee. Debt shuffle buys time amid going concern doubts.
8-K
Annual meeting results
Outlook Therapeutics' stockholders at the March 10, 2026 annual meeting elected Yezan Haddadin, Faisal G. Sukhtian, and Kurt J. Hilzinger as Class I directors until 2029, with 50.70% turnout from 73.5M shares. They ratified KPMG as auditors for fiscal 2026 with strong 35.6M for votes. Say-on-pay passed narrowly. Board continuity intact.
8-K
FDA Type A meeting update
Outlook Therapeutics held a Type A meeting with the FDA on March 5, 2026, to address the December 30, 2025 CRL on its ONS-5010 BLA for wet AMD, focusing on substantial evidence of effectiveness. The company plans ongoing talks to align on confirmatory data from NORSE TWO and EIGHT trials, which showed strong visual acuity gains and clean safety. No approval timeline set. FDA alignment elusive.
8-K
Nasdaq bid price deficiency notice
Outlook Therapeutics received a Nasdaq notice on February 18, 2026, for its common stock closing below $1.00 per share for 30 consecutive business days, violating Listing Rule 5550(a)(2). No immediate delisting; the company has until August 17, 2026, to sustain $1.00 closes for 10 business days. It plans to monitor and explore options like a reverse split. Low price signals distress.
IPO
Employees
Sector
Industry
ADVM
Adverum Biotechnologies, Inc.
4.36+0.00
KLRS
Kalaris Therapeutics, Inc.
8.66+0.16
LCTX
Lineage Cell Therapeutics, Inc.
1.80+0.08
LENZ
LENZ Therapeutics, Inc.
16.70-0.38
LYRA
Lyra Therapeutics, Inc.
3.86-0.07
OCS
Oculis Holding AG
19.84-0.63
OCUL
Ocular Therapeutix, Inc.
14.39+0.22
OKYO
OKYO Pharma Limited
1.88-0.01
OPT
Opthea Limited
3.41+0.00
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00